Jeffrey Drebin

Jeffrey Drebin is a surgeon and scientist. He serves as the Department of Surgery Chair at Memorial Sloan Kettering.[1]

Jeffrey Drebin

Biography

Drebin earned his MD and PhD from Harvard Medical School, before completing his general surgery residency, and surgical oncology fellowship, at Johns Hopkins Medical School.[2] His PhD research, performed with Mark Greene and Robert Weinberg, involved the creation of monoclonal antibodies targeting the Her2/neu protein and demonstrating in preclinical models that such antibodies could inhibit cancer cell growth in vitro and in vivo.[3] This work was focused on targeted cancer therapy and the creation of the drugs trastuzumab (Herceptin) and pertuzumab (Perjeta).[4]

Career

In 1995, after finishing his residency, Drebin became an Assistant Professor of Surgery at Washington University School of Medicine.[5] He became an Associate Professor in 1999, and then a full Professor of Surgery and of Molecular Biology & Pharmacology in 2002.[1] Drebin began working at Penn Medicine in 2004, when he was hired as Chief of the Division of Gastrointestinal Surgery.[6] In 2009, he was named Chair of the Department.[1][6] While there, he joined a Stand Up to Cancer “Dream Team” against pancreatic cancer as a co-Principal Investigator alongside Craig B. Thompson.[7][8][9] In 2017, Drebin moved to Memorial Sloan Kettering to become Department of Surgery Chair.[1] In addition to his responsibilities as Chair, he provides surgical treatments for patients with pancreatic, gallbladder, bile duct, liver, and stomach cancers. His research focuses on the development of new targeted therapies.[1]

Other roles
  • President, Society of Clinical Surgery (2010-2012)
  • President, Philadelphia Academy of Surgery (2014)
  • President, Society of Surgical Oncology (2015)[1]

Awards

References
  1. "Jeffrey Drebin Named Department of Surgery Chairman at Memorial Sloan Kettering". Targeted Oncology. Retrieved 2018-07-20.
  2. "Jeffrey Drebin Bio" (PDF). Retrieved 7 August 2018.
  3. Drebin, J. A.; Link, V. C.; Stern, D. F.; Weinberg, R. A.; Greene, M. I. (1 July 1985). "Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies". Cell. 41 (3): 697–706. doi:10.1016/s0092-8674(85)80050-7. ISSN 0092-8674. PMID 2860972. S2CID 26000048.
  4. Akbarzadeh-Sharbaf, Soudabeh; Yakhchali, Bagher; Minuchehr, Zarrin; Shokrgozar, Mohammad Ali; Zeinali, Sirous (2013). "Expression Enhancement in Trastuzumab Therapeutic Monoclonal Antibody Production using Genomic Amplification with Methotrexate". Avicenna Journal of Medical Biotechnology. 5 (2): 87–95. ISSN 2008-2835. PMC 3689561. PMID 23799177.
  5. "Introducing new faculty members" (PDF). Washington University Record. 9 November 1995. p. 7. S2CID 36415565. Retrieved 7 August 2018.
  6. "Drebin Appointed Chair of Surgery at MSKCC". cancerletter.com. 9 December 2016. Retrieved 7 August 2018.
  7. "Univ. of Pa. wins $18M for pancreatic cancer| 6abc.com". 6abc Philadelphia. Retrieved 2018-07-20.
  8. "Health: Stand Up To Cancer Making Big Impact On Fighting Deadly Cancer in Philadelphia". 2012-09-06. Retrieved 2018-07-20.
  9. Auer, Holly (27 March 2013). "Penn Medicine at the Forefront of the Quest to Cure Cancer". www.pennmedicine.org. Retrieved 2018-07-20.
  10. "Institute of Medicine Elects 70 New Members, 10 Foreign Associates : Health and Medicine Division". www.nationalacademies.org. Archived from the original on 2018-01-26. Retrieved 2018-07-20.
  11. "John Rhea Barton Professorship of Surgery | Endowed Professorships | Perelman School of Medicine at the University of Pennsylvania". www.med.upenn.edu. Retrieved 2018-07-20.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.